Sinorda Biomedicine
Guiyang
About Sinorda Biomedicine
Sinorda Biomedicine develops medicine and the industrialization of tumor immunotherapy. Their disease treatment program includes anti-tumor sentinel lymph node t-cell therapy, oncolytic virus therapy, tumor-infiltrating t-cell therapy, natural killer cell therapy, dendritic cell therapy, killer t-cell therapy, and tumor immune index monitoring. They also provide immune cell isolation and cryopreservation, accurate genetic testing, and immune function test.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2019)
- Website: sinorda.com
Canonical: https://fsome.com/organization/sinorda-biomedicine-1488382 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.